A CDC-backed study in four Atlanta-area facilities from 2020–2024 suggests invasive mold infections (IMD) may be more common and deadly than previously thought, with about one-third of hospitalized patients dying.

This is an initial, local estimate meant to establish surveillance benchmarks, not a national incidence rate, and its results may vary by region.

Exposure typically occurs through inhaled spores, open wounds, or contaminated equipment, though the study did not pinpoint exact exposure locations.

Limitations include lack of DNA-based detection for earlier years and exclusion of cystic fibrosis patients; findings are intended as surveillance benchmarks rather than a national figure.

Ongoing surveillance will incorporate DNA-based methods, with attention to potential clusters and questions about regional or pediatric applicability, alongside guidance advising immunocompromised individuals to seek specialist advice rather than self-medicating.

CDC researcher notes this is an early estimate and emphasizes the value of corroborating data from other regions to broaden understanding.

About 35% of IMD patients lacked classic immunosuppression risk factors, with conditions like cirrhosis and end-stage renal disease appearing more commonly among cases.

Findings reflect a baseline, region-specific picture since invasive mold disease is not nationally notifiable and post-discharge data for 2024 were incomplete.

Recent COVID-19 infection markedly worsened IMD outcomes, with higher ICU admission and 90-day mortality among those with current or recent COVID-19.

Notably, some IMD cases occurred in patients without recognized predisposing factors, highlighting an uncertain risk landscape for high-risk groups.

Interpretation guidance: mold exposure in homes is not a major risk; invasive mold disease mainly affects immunocompromised or severely ill patients, with risk factors including cancer therapies, organ transplantation, and critical illness.

Incidence varied by facility type, with academic hospitals showing higher IMD metrics than community hospitals when normalized per beds.